Contact this trialFirst, we need to learn more about you.
Complement Inhibitor
LNP023 for IgA Nephropathy
Recruiting1 awardPhase 3
Las Vegas, Nevada
This trial will test whether LNP023 is better than placebo at reducing proteinuria and slowing renal disease progression in people with primary IgA nephropathy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service